GT Biopharma files Form D for offering of up to $38.96 million
The San Francisco biotechnology company has raised $7.75 million so far from nine investors under a Rule 506(b) exemption.
SEC filing
Latest
2 stories
Tuesday, September 29
Monday, September 21
GT Biopharma expands preferred stock offering to $7.75 million with new investor
The company amended its Series M preferred stock and warrant sale to add a new purchaser, raising the deal's aggregate stated value and increasing authorized preferred shares.
SEC filing (2)